Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  CNS THERAPEUTICS
A Global Strategic Business Report

This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product Groups analyzed are Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 132 companies including many key and niche players worldwide such as Abbott Laboratories, Akzo Nobel NV, Organon N.V., Alkermes, Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, CeNeS Pharmaceuticals PLC, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Elan Corporation PLC, Eli Lilly and Co, Fabre-Kramer Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceutica NV, Janssen-Cilag, Merck & Co, Inc., Neurocrine Biosciences, Inc., Novartis AG, Sandoz International GmbH, Organon N.V., Ortho-McNeil Neurologics, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi-Aventis, Schwarz Pharma AG, Sepracor, Inc., Shire PLC, Solvay Pharmaceuticals S.A., Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd, UCB S.A., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1835  PAGES:    513
PRICE:    $3950  DATE:       May 2008
COMPANIES:  132  MARKET DATA TABLES:   158
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  CNS THERAPEUTICS (Complete Report) Pages : 513   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS7$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
CNS Disorders.....I-3
A. Anti-Alzheimer's Drugs.....I-3
  
   B. Anti-Parkinson's Drugs.....I-4
C. Anti-Epilepsy Drugs.....I-4
D. Pain Management Drugs.....I-4
  
   E. Anti-Psychotics Drugs.....I-5
(i) Bipolar disorder.....I-5
(ii) Schizophrenia.....I-5
F. Anti-Depressants Drugs.....I-5
  
   G. Others.....I-6
(i) Attention Deficit Hyperactivity Disorder.....I-6
(ii) Multiple Sclerosis.....I-6
(iii) Insomnia.....I-6
  
   (iv) Restless Legs Syndrome.....I-7
(v) Anxiety.....I-7
  
II. EXECUTIVE SUMMARY100$2250
  1. Industry Overview.....II-111 $1100  
   Factors Influencing Demand.....II-1
The ‘Age Factor’.....II-1
Role of Diagnostic Techniques.....II-1
Increasing Disease Awareness.....II-1
Emergent Technologies.....II-1
1$100
   Reimbursement Policies.....II-2
Market Trends and Issues.....II-2
Booming Therapeutic Opportunities for Neuro-Degenerative Disorders.....II-2
Spur in CNS Drug Delivery Technologies.....II-2
1$100
   Migraine Market Offers Growth Opportunities to Prophylaxis Products.....II-3
Demand for Therapeutic Peptides Spurred by Dearth of Effective Therapies.....II-3
Anti-Depressants.....II-3
1$100
   Major Trends in the Depression Market.....II-4
SSRIs are the Preferred Choice Despite Side Effects.....II-4
1$100
   Table 1: US Anti-Depressants Market (2004-2006): Sales of Leading Drug Brands - Zoloft, Effexor ER, Lexapro, Wellbutrin, Paxil, Celexa and Prozac (In US$M) (includes corresponding Graph/Chart).....II-5

Table 2: Leading Brands in European Anti-Depressants Market (2005): Percentage Breakdown by Value Sales for Effexor, Zoloft, Paxil, Cipralex, Wellbutrin, Citalopram, Prozac, Remeron and Others (includes corresponding Graph/Chart).....II-5
Attention Deficit Hyperactivity Disorder (ADHD).....II-5
1$300
   Table 3: Worldwide ADHD Market (2005): Sales of Leading Drug Brands –Concerta, Adderall/ Adderall ER and Strattera (includes corresponding Graph/Chart).....II-6
Major Trends in the ADHD Market:.....II-6
Anti-Psychotics Market.....II-6
1$300
   Restrictions on Promotion Hamper Market Prospects.....II-7
Table 4: Worldwide Atypical Anti-Psychotics Market (2004 & 2005): Sales of Leading Drug Brands – Zyprexa, Risperdal, Seroquel, Abilify and Zeldox (includes corresponding Graph/Chart).....II-7
1$300
   Table 5: Leading Brands in Worldwide Anti-Psychotics Market (Bipolar Disorder) (2003-2005): Percentage Breakdown by Value Sales for Zyprexa, Risperdal, Seroquel, Abilify and Others (includes corresponding Graph/Chart).....II-81$300
   Table 6: Leading Brands in US Anti-Psychotics Market (2004-2006): Percentage Breakdown by Value Sales for Zyprexa, Risperdal, Seroquel, Depakote/ER, Abilify, Lamictal/XR, Geodon and Others (includes corresponding Graph/Chart).....II-91$300
   Table 7: Leading Brands in European Atypical Anti-Psychotics Market (2004): Percentage Breakdown by Value Sales for Zyprexa, Risperdal/ Risperdal CONSTA, Seroquel, Solian, Risperidone, Geodon and Others (includes corresponding Graph/Chart).....II-10
Insomnia.....II-10
Anti-Insomnia Drugs from Corporate Giants Flood the Sleep Market.....II-10
Neuropathic Pain.....II-10
1$300
   Table 8: Leading Players in the US Pain Management Market (2005): Percentage Breakdown by Value Sales for J&J, Endo Pharmaceuticals, Purdue Pharma, Cephalon, King/Ligand and Others (includes corresponding Graph/Chart).....II-11
Patent Expiry of Leading CNS Drugs: 2005-2017.....II-11
1$300
  2. Global Market Analysis.....II-121 $100  
   By Region.....II-12
By Segment.....II-12
1$100
  3. CNS Disorders – An Introduction.....II-1322 $1200  
   Definition.....II-13
Central Nervous System.....II-13
Mortality Threat of CNS Disorders.....II-13
Science of NMDA Receptors and its Disease Significance.....II-13
1$100
   Major CNS Disorders:.....II-14
Alzheimer’s Disease.....II-14
Alzheimer’s Affect on Brain.....II-14
1$100
   Causes for Alzheimer’s.....II-15
Who Are at Risk?.....II-15
1$100
   Prevalence of Alzheimer’s Disease.....II-16
Table 9: Incidence of Alzheimer’s Disorder in Major US States: 2000-2025 (includes corresponding Graph/Chart).....II-16
1$300
   Table 10: Leading Brands in the US Anti-Alzheimer’s Market (2004-2005): Percentage Breakdown by Value Sales for Aricept, Namenda, Razadyne/ Razadyne ER and Exelon (includes corresponding Graph/Chart).....II-17
Diagnosis of Alzheimer’s.....II-17
Treatment for Alzheimer’s.....II-17
1$300
   Parkinson’s Disease.....II-18
Table 11: Leading Brands in Worldwide Anti-Parkinson’s Disease Market (2005): Percentage Breakdown by Value Sales for Mirapex, Requip, Cabaser, Madopar, Stalevo and Others (includes corresponding Graph/Chart).....II-18
1$300
   Prevalence of Parkinson’s.....II-19
Symptom of Parkinson’s.....II-19
Causes of Parkinson’s.....II-19
1$100
   Parkinson’s Diagnosis.....II-20
Therapies for Parkinson’s.....II-20
Surgery: The Last Option.....II-20
1$100
   Epilepsy.....II-21
Table 12: Worldwide Epilepsy Market (2004-2005): Sales of Leading Drug Brands – Topamax, Lamictal, Depakote, Neurontin and Trileptal (In US$ Million) (includes corresponding Graph/Chart).....II-21
Therapies for Epilepsy.....II-21
1$300
   Pain Management.....II-221$100
   Debilitating Effects of Pain.....II-23
Types of Pain.....II-23
Acute Pain.....II-23
Chronic Pain.....II-23
Migraine.....II-23
Neuropathic Pain.....II-23
1$100
   Nociceptive Pain.....II-24
Pain Management Therapies.....II-24
Bipolar Disorder.....II-24
Symptoms of Bipolar Disorder.....II-24
1$100
   Therapies for Bipolar Disorder.....II-25
Schizophrenia.....II-25
Symptoms of Schizophrenia.....II-25
Therapies for Schizophrenia.....II-25
Depression.....II-25
1$100
   Prevalence of Depression.....II-26
Causes of Depression.....II-26
Types of Depressive Disorders.....II-26
Available Treatment.....II-26
1$100
   Tricyclic Antidepressants.....II-27
Monoamine Oxidase Inhibitors.....II-27
Lithium Salts.....II-27
Working of Antidepressants.....II-27
Ranking of Antidepressants in Terms of Efficacy.....II-27
1$100
   Types of Antidepressants.....II-28
NMDA Receptor Antagonists.....II-28
NMDA Receptor (NMDAR).....II-28
NMDA Receptor Agonists.....II-28
Acetylcholinesterase Inhibitors.....II-28
1$100
   Selective Serotonin Reuptake Inhibitors (SSRIs).....II-29
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs).....II-29
1$100
   Others Common CNS Disorders.....II-30
Attention Deficit Hyperactivity Disorder.....II-30
Consequences of ADHD.....II-30
1$100
   What Leads to ADHD?.....II-31
Treating ADHD.....II-31
Multiple Sclerosis (MS).....II-31
1$100
   Types of Multiple Sclerosis.....II-32
Prevalence of MS.....II-32
Causes of MS.....II-32
Myths Surrounding Multiple Sclerosis.....II-32
1$100
   Symptoms of MS.....II-33
Diagnosis of MS.....II-33
Therapies for MS.....II-33
Insomnia.....II-33
Prevalence of Insomnia.....II-33
1$100
   Therapies for Insomnia.....II-34
Restless Legs Syndrome.....II-34
Anxiety.....II-34
1$100
  4. Overview of Select CNS Drugs.....II-356 $600  
   Anti-Alzheimer’s Drugs.....II-35
Aricept.....II-35
Exelon.....II-35
Reminyl.....II-35
Ebixa.....II-35
Namenda.....II-35
1$100
   Anti-Parkinson’s Drugs.....II-36
Levodopa.....II-36
Dopamine Agonists.....II-36
Mirapex.....II-36
Requip.....II-36
Anti-Epilepsy Drugs.....II-36
Carbamazepine.....II-36
Phenytoin.....II-36
1$100
   Lamictal.....II-37
Depakote.....II-37
Neurotonin.....II-37
Pain Management.....II-37
Duragesic.....II-37
Metabotropic Glutamate Receptors (mGluRs).....II-37
1$100
   Anti-Psychotics.....II-38
Zyprexa.....II-38
Seroquel.....II-38
Abilify.....II-38
Clozaril.....II-38
Antidepressants Drugs.....II-38
Zoloft (Sertraline).....II-38
1$100
   Prozac (Fluoxetine).....II-39
Effexor (Venlafaxine).....II-39
Paxil.....II-39
Wellbutrin (Bupropion).....II-39
Attention Deficit Hyperactivity Disorder (ADHD).....II-39
Concerta.....II-39
1$100
   Strattera.....II-40
Adderall.....II-40
Insomnia.....II-40
Estorra.....II-40
Lunesta.....II-40
1$100
  5. Research & Development.....II-416 $600  
   AstraZeneca, NPS Develop mGluRs for CNS Disorders.....II-41
High Efavirenz Plasma Levels in HIV Patients Could Result in CNS Toxicity.....II-41
Adenoviral Gene Therapy May Damage CNS.....II-41
Role of B Cells in Damaging Nerve Fibers.....II-41
1$100
   Oral Administration of Antibodies Restrict Attacks in MS.....II-42
Country of Birth/Dwelling Influences Risk of Multiple Sclerosis.....II-42
Levetiracetam is Effective in Epilepsy Prevention.....II-42
Nicotine Guards Against Parkinson’s-Like Disease.....II-42
1$100
   Parkinson’s Drugs May Influence Addictions.....II-43
Dopamine Induces Sleep and Brain Activity.....II-43
Researchers Link Obesity to Dementia.....II-43
High Folate Consumption Mitigates Risks to Alzheimer’s Disease.....II-43
Consistent Depression Treatment Likely to Prevent Relapse.....II-43
Animal Research Model Highlights Difficulties of Depression Syndrome.....II-43
1$100
   Hypnion Announces Encouraging Results for HY10275.....II-44
Antihistamine Effective In Mitigating Alzheimer’s Disorder.....II-44
Novartis’ Fingolimod Alleviate MS Activity.....II-44
Lundbeck Initiates Trials of its Novel Anti-Psychotic Drug.....II-44
Cara Develops CR665 for Pain Management.....II-44
Gepirone ER of Fabre-Kramer Effective in Depression.....II-44
1$100
   Biogen Idec Discovers Molecule for Treatment of CNS Disorders.....II-45
Teva Claims Copaxone as the Ultimate in Treating MS.....II-45
Biogen Idec and Elan Corp. Conclude Safety Evaluation of Tysabri®.....II-45
Cognetix Files Provisional Patent for Screening Methods of CGX-1160.....II-45
NeuroSearch’s NS2330 Fail to Meet Efficacy Standards in Trials.....II-45
Medtronic Undertakes Trials to Study Treatment Resistant Depression.....II-45
National MS Society to Initiate Efforts to Identify MS Influencing Genetics.....II-45
1$100
   Academic Data Supports COMT Inhibitors Performance in Parkinson’s.....II-46
MS Ireland Supports Return of Tysabri.....II-46
Cigarette Smoking Increases Risks of Multiple Sclerosis.....II-46
Study of Parkinson’s Incidence in Zambia, Russia and Uzbekistan.....II-46
Encouraging Developments in Animal Model of Parkinson’s Disease.....II-46
1$100
  6. Product Innovations/Introductions.....II-472 $200  
   Biogen and Elan Introduces Tysabri in Europe.....II-47
Medtronic Launches Activa® for Parkinson’s Disease.....II-47
Tysabri Obtains Canadian Approval For Multiple Sclerosis.....II-47
Lundbeck Unveils Serdolect® Available in Estonia.....II-47
OPC, Bristol-Myers Unveil Abilify® Discmelt™.....II-47
OPC Introduces Anti-Psychotic Drug Abilify in Japan.....II-47
1$100
   FDA Approves Novartis’ Exelon for Parkinson’s.....II-48
Ono Pharmaceutical, Novartis Develops Transdermal Patch for Alzheimer’s.....II-48
Zydus Cadila Drugs Flood the French Pharmaceutical Market.....II-48
Schwarz Pharma Develops Anti-Parkinson’s Drug.....II-48
Azilect® Enters European Market.....II-48
Lilly Launches Therapy for Bipolar Disorder.....II-48
1$100
  7. Recent Industry Activity.....II-4918 $1000  
   P1vital Creates Global Consortium to Develop CNS Experimental Medicine.....II-49
Neurobiological Tech Teams Up with Buck Institute.....II-49
ExonHit Therapeutics and Allergan Ink Contract to Develop CNS Agents.....II-49
NeuroSearch Commences Clinical Phase I study with NSD-788 in France.....II-49
Abilify® Meets CHMP Standards.....II-49
UCB Receives Recommendation for Approval for Neupro®.....II-49
1$100
   Schering-Plough Acquires Organon.....II-50
UCB Launches Neupro® in the US.....II-50
GlaxoSmithKline Forms Alliance with Targacept.....II-50
GSK Teams-Up with Sepracor for Commercializing Lunivia®.....II-50
1$100
   US FDA Rebut NDA for bifeprunox.....II-51
Medtronic and Alnylam Extend their Drug-Device Collaboration.....II-51
Neuren Takes Over Hamilton.....II-51
Roche Forms Partnership with Synosis Therapeutics to Evaluate Five CNS
  Compounds.....II-51
NeuroSearch Starts Clinical Phase I Study with ACR343 in Sweden.....II-51
Lundbeck to Promote Circadin® in Europe.....II-51
1$100
   Sepracor Inks Partnership with Eisai to Develop and Market Lunesta® in Japan.....II-52
Neurologix Obtains License of Gene Therapy Component.....II-52
Prestwick Raises Fund to Finance CNS Projects.....II-52
Kyowa Inks Agreement with Britannia.....II-52
1$100
   China Aoxing Pharmaceutical Receives Product Approvals.....II-53
China Aoxing Acquires Hebei Aoxing.....II-53
AlphaRx Partners with Israel based PharmSeed Ltd.....II-53
Nippon Boehringer Markets CNS Drugs on Portals.....II-53
FDA Approves Tysabri for treating MS.....II-53
CeNeS Acquires Certain IP Rights from ALZA.....II-53
1$100
   Belgium based UCB Acquires Schwarz Pharma.....II-54
Axaron and LION Bioscience Establish New Company.....II-54
Ceregene Obtains Grant for Phase II Trial.....II-54
Shire Obtains Anti-Epileptic Drug License from Yissum.....II-54
TorreyPines and Axonyx Conclude Merger Operations.....II-54
VistaGen Enters Into Strategic Partnership with Cato BioVentures.....II-54
1$100
   Organon Announces Partnership with BrainCells.....II-55
Alkermes Inks Licensing Agreement with Rensselaer.....II-55
FDA Approves SEROQUEL® Therapy for Bipolar Indication.....II-55
Boehringer Ingelheim, Eli Lilly Modify Agreement Terms .....II-55
Boston Life Sciences Signs Licensing Agreement with Children’s Hospital.....II-55
CeNeS, Tripos Extend Research Collaboration.....II-55
1$100
   CeNeS Partners Ergomed for CNS 5161 Phase II Clinical Trial.....II-56
CeNeS’ Short-Acting Sedative Obtains Patent.....II-56
Takeda and Cephalon Collaborate Over Provigil®.....II-56
Eli Lilly Files sNDA for Cymbalta®.....II-56
GlaxoSmithKline Obtains FDA Approval for Lamictal®.....II-56
Serono Acquires Safinamide License from Neuron.....II-56
Neurocrine Files NDA for Anti-Insomnia Drug Indiplon.....II-56
1$100
   Novartis Inks Agreement with Servier, Idenix.....II-57
NPS Extends Alliance with AstraZeneca.....II-57
Pfizer’s Lyrica® Receives Approval for Neuropathic Pain.....II-57
Schwarz Pharma Receives FDA Approval of Neupro®.....II-57
Teva’s Azilect® tablets Approved in Canada.....II-57
Teva and Eisei Terminate Joint Marketing Alliance.....II-57
1$100
   FDA Approves Teva’s Azilect® for Parkinson’s Disorder.....II-58
UCB’s Keppra® Obtains FDA Approval to Treat Epilepsy.....II-58
Wyeth, Solvay Pharmaceuticals Files NDA for Schizophrenia Drug.....II-58
D-Pharm Licenses DP-b99 Drug to Yungjin.....II-58
Eli Lilly, Suven Collaborate Over CNS Therapies.....II-58
IVAX to Develop Oral Therapy for Multiple Sclerosis.....II-58
Thomson Takes Over Cipher’s Business Unit.....II-58
1$100
   CLL Pharma Acquires Synt: em SA.....II-59
Ranbaxy Acquires Advent’s Subsidiary.....II-59
Shire Receives Approval of Daytrana for Treating ADHD Disorder.....II-59
Shire Inks Marketing Agreement with New River.....II-59
Acadia and Sepracor in a Collaborative R&D Deal.....II-59
Ablynx Partners with National Research Council of Canada.....II-59
1$100
   Bristol Myers and Albany Sign Licensing Agreement.....II-60
Andara Secures Licenses to Purdue’s Treatment Alternatives.....II-60
Otsuka Ties Up with Galenea to Develop CNS drugs.....II-60
Novartis Inks Distribution Agreement with Alfresa Pharma.....II-60
Dainippon Commences Operations of New Facility.....II-60
Ranbaxy Purchases Generic Product Line of Efarmes.....II-60
1$100
   Novasite Takes Over PsyCheNomicS.....II-61
Organon Returns Gepirone ER Rights to Fabre-Kramer.....II-61
Teva Expands Operations in India.....II-61
Neurologix Acquires License to Alzheimer’s Treating Gene.....II-61
Meda Takes Over Viatris.....II-61
Evotec Acquires Majority Stake in Evotec Neurosciences.....II-61
1$100
   IVAX Merges with Teva Pharmaceutical.....II-62
Wyeth Files NDA for Anti-Depressant Drug DVS-233.....II-62
Schwarz Pharma Acquires Rights of Rotigotine.....II-62
Shire Submits NDA for Two ADHD Drugs.....II-62
Takeda and Paradigm Collaborate to Develop CNS Therapies.....II-62
Sanofi’s Ambien CR™ to Induce and Maintain Sleep in the US.....II-62
NeuroSearch Initiates Phase I Clinical Study of ABT- 894.....II-62
NeuroSearch Receives Euro 10 Million as Milestone Payments for NS2359.....II-62
1$100
   FDA Approves Depakote® ER for Bipolar Disorder Treatment.....II-63
Alkermes Receives Approval for Risperdal Consta® in Italy.....II-63
AstraZeneca Signs Research Collaboration Deal with Targacept.....II-63
Cymbalta® / Xeristar® Treatment Approved for Depression in Europe.....II-63
FDA Grants SPA Status to Boston Life’s Altropane®.....II-63
Sumitomo Merges with Dainippon.....II-63
Cipralex® Therapy Extended to GAD in Europe.....II-63
1$100
   Johnson & Johnson Submits Paliperidone ER for NDA.....II-64
Spectrum Acquires License of CNS Cancer Therapeutic Drug.....II-64
Multiple Sclerosis Drug Tysabri Pulled Off Market.....II-64
Roche Partners with GE Healthcare.....II-64
New River to Develop Pain Management Therapies.....II-64
Elekta Takes Over IMPAC Medical Systems.....II-64
Eli Lilly Acquires Merck’s Product Compound for Insomnia.....II-64
1$100
   Prestwick Raises Funds to Develop CNS Therapies.....II-65
Aspect Medical Acquires Exclusive Rights to Cordance Technology.....II-65
Bristol-Myers Pulls Out Serzone from the US Market.....II-65
Paladin Inks Agreement with Ovation.....II-65
Acorda Raises Funds For Therapy Development.....II-65
Wyeth Sells Indiplon Ownership Rights to Neurocrine.....II-65
1$100
   Micrologix Takes Over Mitokor.....II-66
Sanofi Merges with Aventis to Form a New Company.....II-66
VistaGen Takes Over Artemis.....II-66
Neuro Bioscience Acquires Majority Stake in CLL Pharma.....II-66
Tiger Brands Acquires Pfizer’s Subsidiary.....II-66
Pfizer Acquires Asenapine License from Organon.....II-66
1$100
  8. Focus on Select Global Players.....II-6710 $700  
   Abbott Laboratories (USA).....II-67
Alkermes, Inc. (USA).....II-67
AstraZeneca Plc (UK).....II-67
Boehringer Ingelheim GmbH (Germany).....II-67
1$100
   Bristol-Myers Squibb (USA).....II-68
CeNeS Pharmaceuticals Plc (UK).....II-68
Cephalon, Inc. (USA).....II-68
1$100
   Dainippon Sumitomo Pharma Co., Ltd. (Japan).....II-69
Elan Corporation Plc (Ireland).....II-69
Eli Lilly and Co. (USA).....II-69
1$100
   Fabre-Kramer Pharmaceuticals, Inc. (USA).....II-70
F. Hoffmann-La Roche Ltd. (Switzerland).....II-70
Forest Laboratories, Inc. (USA).....II-70
GlaxoSmithKline (UK).....II-70
1$100
   H. Lundbeck A/S (Denmark).....II-71
Johnson & Johnson (USA).....II-71
Janssen Pharmaceutica N.V. (Belgium).....II-71
Janssen-Cilag (Switzerland).....II-71
Merck & Co, Inc. (USA).....II-71
1$100
   Neurocrine Biosciences, Inc. (USA).....II-72
Novartis AG (Switzerland).....II-72
Sandoz International GmbH (Germany).....II-72
1$100
   Organon N.V. (The Netherlands).....II-73
Ortho-McNeil Neurologics, Inc. (USA).....II-73
Otsuka Pharmaceutical Co., Ltd. (Japan).....II-73
Pfizer, Inc. (USA).....II-73
1$100
   Sanofi-Aventis (France).....II-74
Schwarz Pharma AG (Germany).....II-74
Sepracor, Inc. (USA).....II-74
Shire Plc (UK).....II-74
1$100
   Solvay Pharmaceuticals S.A. (France).....II-75
Takeda Pharmaceutical Co., Ltd. (Japan).....II-75
Teva Pharmaceutical Industries Ltd. (Israel).....II-75
UCB S.A. (Belgium).....II-75
1$100
   Wyeth (USA).....II-76
1$100
  9. Global Market Perspective.....II-77   
   Table 13: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-771$300
   Table 14: World Long-term Projections for CNS Therapeutics by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-781$300
   Table 15: World 10-Year Perspective for CNS Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-791$300
   Table 16: World Recent Past, Current & Future Analysis for Anti-Alzheimer's Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-801$300
   Table 17: World Long-term Projections for Anti-Alzheimer's Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-811$300
   Table 18: World 10-Year Perspective for Anti-Alzheimer's Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-821$300
   Table 19: World Recent Past, Current & Future Analysis for Anti-Parkinson's Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-831$300
   Table 20: World Long-term Projections for Anti-Parkinson's Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-841$300
   Table 21: World 10-Year Perspective for Anti-Parkinson's Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-851$300
   Table 22: World Recent Past, Current & Future Analysis for Anti-Epilepsy Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-861$300
   Table 23: World Long-term Projections for Anti-Epilepsy Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-871$300
   Table 24: World 10-Year Perspective for Anti-Epilepsy Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-881$300
   Table 25: World Recent Past, Current & Future Analysis for Pain Management Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-891$300
   Table 26: World Long-term Projections for Pain Management Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-901$300
   Table 27: World 10-Year Perspective for Pain Management Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-911$300
   Table 28: World Recent Past, Current & Future Analysis for Anti-Psychotics Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-921$300
   Table 29: World Long-term Projections for Anti-Psychotics Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-931$300
   Table 30: World 10-Year Perspective for Anti-Psychotics Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-941$300
   Table 31: World Recent Past, Current & Future Analysis for Anti-Depressants Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-951$300
   Table 32: World Long-term Projections for Anti-Depressants Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-961$300
   Table 33: World 10-Year Perspective for Anti-Depressants Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-971$300
   Table 34: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-981$300
   Table 35: World Long-term Projections for Other Drugs by Geographic Region – USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-991$300
   Table 36: World 10-Year Perspective for Other Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Europe, Asia-Pacific (including Japan), Latin America and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1001$300
III. MARKET91$1950
  1. The United States.....III-128 $1350  
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
Cost Implications of CNS Disorders.....III-1
Alzheimer's Market.....III-1
1$75
   Table 37: Incidence of Alzheimer's Disorder in Major US States: 2000-2025 (includes corresponding Graph/Chart).....III-2
Anti-Alzheimer's Drugs Approved for Use in the Past.....III-2
1$150
   Table 38: Leading Brands in the US Anti-Alzheimer's Market (2004 & 2005): Percentage Breakdown by Value Sales for Aricept, Namenda, Razadyne / Razadyne ER and Exelon (includes corresponding Graph/Chart).....III-3
Cost of Care to AD Patient.....III-3
Clinical Pipeline.....III-3
Anti-Psychotics.....III-3
1$150
   Growth Dampeners.....III-4
Clinical Pipeline.....III-4
1$75
   Table 39: Leading Brands in US Anti-Psychotics Market (2004-2006): Percentage Breakdown by Value Sales for Zyprexa, Risperdal, Seroquel, Depakote/ER, Abilify, Lamictal/XR, Geodon and Others (includes corresponding Graph/Chart).....III-5

Table 40: Leading Brands in US Atypical Anti-Psychotics Market (2004, 2006 & 2008): Percentage Breakdown by Value Sales for Zyprexa, Risperdal/ Risperdal CONSTA, Seroquel, Abilify, Geodon and Others (includes corresponding Graph/Chart).....III-5
1$150
   Antidepressants.....III-6
Antidepressants to Feature Black-Box Warnings.....III-6
Antidepressant Consumption Falls Among Children and Adolescents.....III-6
Table 41: US Anti-Depressants Market (2004-2006): Sales of Leading Drug Brands – Zoloft, Effexor ER, Lexapro, Wellbutrin, Paxil, Celexa and Prozac (includes corresponding Graph/Chart).....III-6
1$150
   Multiple Sclerosis.....III-7
Table 42: Leading Anti-Multiple Sclerosis Drugs in the US (2004): Percentage Breakdown of Value Sales for Avonex, Copaxone, Rebif and Betaseron (includes corresponding Graph/Chart).....III-7
Insomnia Market.....III-7
Rising Consumption of ADHD Drugs Combat Safety Concerns.....III-7
1$150
   Table 43: US ADHD Market (2005): Percentage Breakdown of Sales by Leading Brands – Concerta, Strattera, Ritalin, Metadate, Focalin XR and Others (includes corresponding Graph/Chart).....III-8
Unmet Medical Needs in Neuropathic Pain Offer Growth Prospects.....III-8
Table 44: Leading Players in the US Pain Management Market (2005-2007): Percentage Breakdown by Value Sales for J&J, ENDO, Purdue, Cephalon, King/Ligand and Others (includes corresponding Graph/Chart).....III-8
1$150
   CNS Tuberculosis Raises its Ugly Head.....III-9
Product Launches/Developments.....III-9
1$75
   Strategic Corporate Developments.....III-1010$575
   Key Players.....III-206$450
   B. Market Analytics.....III-26
Table 45: US Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-26
1$150
   Table 46: US Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-271$150
   Table 47: US 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-28
1$150
  2. Canada.....III-295 $425  
   A. Market Analysis.....III-29
Current & Future Analysis.....III-29
Facts & Figures.....III-29
Strategic Corporate Developments.....III-29
1$75
   Neurochem, Inc. – A Major Player.....III-301$75
   B. Market Analytics.....III-31
Table 48: Canadian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-31
1$150
   Table 49: Canadian Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-321$150
   Table 50: Canadian 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-33
1$150
  3. Europe.....III-3419 $1225  
   A. Market Analysis.....III-34
Current & Future Analysis.....III-34
By Region.....III-34
By Product Segment.....III-34
Anti-Psychotics Market.....III-34
Table 51: European Anti-Psychotics Market (2002-2006): Percentage Breakdown of Revenues by Product Class – Atypical Anti-Psychotics Drugs and Traditional Anti-Psychotics Drugs (includes corresponding Graph/Chart).....III-34
1$150
   Table 52: Leading Brands in European Atypical Anti-Psychotics Market (2004): Percentage Breakdown by Value Sales for Zyprexa, Risperdal/ Risperdal CONSTA, Seroquel, Solian, Risperidone, Geodon and Others (includes corresponding Graph/Chart).....III-35
European CNS Market Offers Untapped Opportunities.....III-35
Competitive Scenario of CNS Drug Market.....III-35
Challenges Faced by the Antidepressants Market.....III-35
1$150
   Table 53: Leading Brands in European Anti-Depressants Market (2005): Percentage Breakdown by Value Sales for Effexor, Zoloft, Paxil, Cipralex, Wellbutrin, Citalopram, Prozac, Remeron and Others (includes corresponding Graph/Chart).....III-36

Table 54: European Anti-Depressants Market (2004-2006): Percentage Breakdown of Revenues by Segment – SSRI, SNRI and Others (includes corresponding Graph/Chart).....III-36
Product Launches/Developments.....III-36
1$150
   Strategic Corporate Developments.....III-375$375
   Key Players.....III-425$375
   B. Market Analytics.....III-47
Table 55: European Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-47
1$150
   Table 56: European Long-term Projections for CNS Therapeutics by Geographic Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-481$150
   Table 57: European Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-491$150
   Table 58: European Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-501$150
   Table 59: European 10-Year Perspective for CNS Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-511$150
   Table 60: European 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-52
1$150
  3a. France.....III-534 $375  
   A. Market Analysis.....III-53
Current & Future Analysis.....III-53
Healthcare System in France.....III-53
1$75
   B. Market Analytics.....III-54
Table 61: French Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-54
1$150
   Table 62: French Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-551$150
   Table 63: French 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-56
1$150
  3b. Germany.....III-574 $375  
   A. Market Analysis.....III-57
Current & Future Analysis.....III-57
Healthcare System in Germany.....III-57
Reimbursement Policy.....III-57
1$75
   B. Market Analytics.....III-58
Table 64: German Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-58
1$150
   Table 65: German Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-591$150
   Table 66: German 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-60
1$150
  3c. Italy.....III-614 $375  
   A. Market Analysis.....III-61
Current & Future Analysis.....III-61
Healthcare System in Italy.....III-61
Market Snapshots.....III-61
1$75
   B. Market Analytics.....III-62
Table 67: Italian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-62
1$150
   Table 68: Italian Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-631$150
   Table 69: Italian 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-64
1$150
  3d. The United Kingdom.....III-654 $350  
   A. Market Analysis.....III-65
Current & Future Analysis.....III-65
Healthcare System in the UK.....III-65
NICE Recommendations on CNS Therapeutics.....III-65
1$75
   B. Market Analytics.....III-66
Table 70: UK Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-66
1$150
   Table 71: UK Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-671$150
   Table 72: UK 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-68
1$150
  3e. Spain.....III-694 $375  
   A. Market Analysis.....III-69
Current & Future Analysis.....III-69
Healthcare System in Spain.....III-69
1$75
   B. Market Analytics.....III-70
Table 73: Spanish Recent Past, Current & Future Analysis for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-70
1$150
   Table 74: Spanish Long-term Projections for CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-711$150
   Table 75: Spanish 10-Year Perspective for CNS Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-72
1$150
  3f. Rest of Europe.....III-734 $375  
   A. Market Analysis.....III-73
Current & Future Analysis.....III-73
Overview of Select Markets.....III-73
Belgium.....III-73
Finland.....III-73
Scandinavia.....III-73
1$75
   Sweden.....III-74
The Netherlands.....III-74
B. Market Analytics.....III-74
Table 76: Rest of Europe Recent Past, Current & Future Analysis CNS Therapeutics by Product Group – Anti-Alzheimer's, Anti-